

TOPOTECAN

Topotecan is only recommended for the treatment of women with platinum-refractory or platinum-resistant ovarian cancer if liposomal doxorubicin and paclitaxel are considered unsuitable.

NICE statement May 2005

| | | | | |
|-------------------------|--|----------------------|----|---|
| Drug / Dosage: | Topotecan | 1.5mg/m ² | IV | Day 1 to Day 5 (5 doses in total per cycle) |
| Administration: | In 100 ml of 0.9 % Sodium Chloride over 30 minutes | | | |
| Frequency: | 3 weekly cycle (from Day 1) Review after 4 cycles Maximum 6 cycles | | | |
| Main Toxicities: | myelosuppression; stomatitis; alopecia; diarrhoea | | | |
| Anti – emetics: | mildly emetogenic | | | |
| Extravasation: | non-vesicant | | | |
| Regular investigations: | FBC | D1 | | |
| | U&Es | D1 | | |
| | LFTs | D1 | | |
| | CA 125 | D1 | | |
| | EDTA | Prior to Cycle 1 | | |
| Comments: | For patients on Cycle 1 whose EDTA is not yet available, Cockcroft & Gault may be used to predict GFR. Topotecan dose should be adjusted if necessary once EDTA available. EDTA should only be repeated if the result is borderline at the start of treatment or if there is a 30% change in serum creatinine. | | | |
| | Patients may receive some/all of their doses at home, administered by the Healthcare at Home team, providing a valid prescription is supplied to pharmacy with sufficient notice. Check with pharmacy if in doubt of current service arrangements. | | | |

Dose Modifications

| | | |
|--|---|--|
| Haematological Toxicity: | Neutrophils < 1.0 x 10 ⁹ /l or Platelets < 100 x 10 ⁹ /l | Delay treatment for 1 week and repeat FBC. If within normal parameters, proceed at full dose. |
| The following patients should have dosage reduced to 1.25mg/m ² /day (or subsequently down to 1mg/m ² /day, if necessary): | | |
| Patients who experience: | Neutrophils < 0.5 x 10 ⁹ /l for 7 days or more or severe neutropenia with fever or infection or have had treatment delayed due to neutropenia or platelets < 25 x 10 ⁹ /l at any point after treatment or Grade 3 – 4 non haematological toxicity | |

| | |
|---|---|
| Reason for Update: NICE guidance update and layout update | Approved by Lead Chemotherapy Nurse: C Palles-Clark |
| Version: 2 | Approved by Consultant: Dr S Essapen |
| Supersedes: Version 1 | Date: 11.3.07 |
| Prepared by: S Taylor | Checked by: S Punter |

Renal Impairment:

| GFR (ml/min) | Topotecan Dose |
|---------------------|------------------------|
| > 60 | Give 100% dose |
| 41 - 60 | Give 75% dose |
| 20 - 39 | Give 50% dose |
| < 20 | Nil – contra indicated |

Reference: Creemers, GJ et al (1996), JCO; 14: 3056 – 3061

| | |
|---|---|
| Reason for Update: NICE guidance update and layout update | Approved by Lead Chemotherapy Nurse: C Palles-Clark |
| Version: 2 | Approved by Consultant: Dr S Essapen |
| Supersedes: Version 1 | Date: 11.3.07 |
| Prepared by: S Taylor | Checked by: S Punter |